Rutgers scientists and TyRx Pharma, Inc., have announced the Food and Drug Administration's clearance of a new medical device for hernia repair that incorporates a biodegradable technology developed at the university. This action signals a paradigm shift in the application of biomaterials from permanent prosthetic replacements toward regenerative medicine, in which materials help the body to repair itself and are then resorbed.

The device consists of a surgical mesh coated with a polymer developed using a Rutgers bioresorbable technology. The polymer gives the surgical mesh improved handling characteristics that facilitate precise placement during the surgical repair and leave less implant material following the resorption of the coating.

Hernias occur when musculature fails and one part of the body protrudes through the resulting gap or opening into another part of the body. And although a hernia can theoretically develop almost anywhere, most are in the groin and abdominal areas.

The partially degradable device has been developed and will be marketed by TyRx Pharma, Inc., a medical device company founded in 1998.

"The company's early research was conducted at the Rutgers-based New Jersey Center for Biomaterials (CBM) in Rutgers' chemistry laboratories," said Joachim Kohn, CBM director and Board of Governors Professor of Chemistry and Chemical Biology at Rutgers, The State University of New Jersey. "This is an example of a close and strong academic-industry interaction that led to a relatively fast entrance of the product into the medical market."

Kohn pointed out that the technology was invented in 1997 and has progressed along a fast and efficient track to FDA approval a process that usually takes 10 years or more.

The invention was made with initial research support from the National Institutes of Health and demonstrates how a federal agency's funding can reap benefits for the American public. On a local level
'"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-816-5838
Rutgers, the State University of New Jersey
3-Jan-2006

Page: 1 2
Related biology news :

1. FDA approves new epilepsy indication for Lamictal
2. US govt approves multi-million $ wild bird avian flu surveillance network
3. FDA approves extended dosing of Aranesp
4. FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections
5. DFG approves additional six research training groups
6. FDA approves ABRAXANE(TM) for metastatic breast cancer
7. Saudi Arabias KAUST names WHOI first research partner
8. Which came first, the moth or the cactus?
9. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
10. Seawater intrusion is the first cause of contamination of coastal aquifers
11. Camera-shy deer caught for first time